Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Breakthrough Pharmaceuticals Inc. is active in the Biotechnology & Pharmaceuticals technology area. The company currently has 1 pending office action. This single action is handled by 1 distinct examiner within 1 distinct art unit. This distribution reflects a localized prosecution environment where all current activity is concentrated under one point of review.
The busiest examiner for this portfolio is HABTE, KAHSAY, who is responsible for 1 pending office action. As this is the only pending action for the company, the entire prosecution strategy is currently focused on this specific individual. This singular point of contact defines the company's current experience with the patent office in this technology area.
The presence of 1 distinct art unit indicates that the subject matter of the pending application is specialized. There are no other art units or examiners involved to provide a comparative baseline for the company's prosecution efforts. This results in a streamlined set of proceedings within the Biotechnology & Pharmaceuticals field.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| HABTE, KAHSAY | 1 | 85.0% | +7.4% |
Cases in front of an examiner with an allow rate of 80%+ where the difficulty is Easy or Medium. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18263702 | SUBSTITUTED PYRIDAZINE PHENOL DERIVATIVES | HABTE, KAHSAY | 62d |
| Art Unit | Apps |
|---|---|
| 1624 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18263702 | SUBSTITUTED PYRIDAZINE PHENOL DERIVATIVES | HABTE, KAHSAY | 1624 | §103 | Non-Final OA | 62d | Pending | Jul 31, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial